Apr 18 |
TG Therapeutics wins VA contract for Briumvi
|
Apr 18 |
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
Apr 18 |
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
|
Apr 17 |
TG Therapeutics: The Cloud Over Briumvi
|
Apr 15 |
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
Apr 12 |
TG Therapeutics: BRIUMVI Development Could Lead To Great Results
|
Mar 19 |
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?
|
Mar 13 |
(TGTX) - Analyzing TG Therapeutics's Short Interest
|
Mar 13 |
13 Best Biotech Stocks To Buy Under $20
|
Mar 8 |
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|